CRDO down 23% in a month as the sell-off deepens

Credo Technology has now shed 23% over the past month, closing at $147.29 on Friday, and the week added a further 13.2% to that loss. The prior note flagged a stock already under pressure. Since then the decline has accelerated, the short base has edged higher, and retail attention has spiked to historically elevated levels for the name.

Short positioning has grown meaningfully through the slide. Short interest reached 5.86% of the free float on October 22, up 37% over the past month, and nudged higher again on the most recent daily reading. The key point is that the build predated the sharpest part of the sell-off and has not reversed as the stock fell, which suggests the short side remains convicted rather than caught offside. Borrow conditions, however, give no sign of squeeze risk. Availability is extremely loose at 2,329%, meaning roughly 23 shares remain available to borrow for every one already shorted. That ratio has actually risen sharply over the past week as short demand eased even while the stock declined. Cost to borrow has halved over the same period to 0.25%, also close to the lowest reading in the history window. The lending market is not tightening; shorts can add or maintain positions cheaply and freely.

Options positioning is unremarkable relative to the drama in the stock itself. The put/call ratio stands near its 20-day average at 0.98, with a z-score of essentially zero. The 52-week range runs from 0.68 to 1.36, so the current reading is squarely in the middle. Whatever conviction is driving the sell-off is not being amplified by a notable options skew in either direction. Wikipedia attention, on the other hand, has jumped to a z-score of 2.7 against the company's own 90-day history, the highest retail-attention reading in that window. Elevated public interest during a sharp decline often reflects forced recognition rather than fresh buying intent.

The Street still broadly likes the stock, but has been walking targets lower for weeks. Most of the post-Q4 analyst response involved maintained ratings paired with lower price targets: JPMorgan held Overweight but cut to $310, BofA kept Buy while dropping to $275, and Stifel trimmed to $310 from $350 earlier this month. Rosenblatt is the lone dissenter, sitting at Neutral with a $235 target. The consensus mean of $284 implies roughly 93% upside from the current price, a gap that reflects how far the stock has fallen rather than a change in analyst conviction. Valuation multiples confirm the compression: the price-to-book ratio has dropped 2.6 points over the past 30 days, and the PE multiple has fallen nearly 8 points over the same window, both mechanical consequences of a stock off nearly a quarter. The ORTEX short score is a middling 38, down from above 39 a fortnight ago, consistent with a picture where bears are present but not at extreme levels.

The bull case rests on Q4 results that were genuinely strong: $437 million in revenue, up 157% year-over-year, with roughly 68% gross margins and FY27 growth guided around 70%. The company carries about $1.4 billion in cash and generated over $175 million in free cash flow. Bears counter that the 800G AEC market is getting more crowded as Marvell and Broadcom press harder, the push into optical targets a lower-margin space without a clear moat, and four customers account for around 87% of revenue. One program pause would be visible immediately in the numbers. The stock's own earnings history gives context: the Q4 print on October 12 sent the stock down 8.4% on the day and a further 20% over the following week. The prior earnings event, reported September 1, resulted in a 27% single-day decline and a 26% five-day loss. Both drops were sharp and showed little immediate recovery.

Insider activity in the immediate period is all planned sales executed under 10b5-1 programmes, which limits their signal value. CTO Chi Fung Cheng sold roughly 20,000 shares across multiple tranches on October 20 at prices between $162 and $174, totalling around $3.6 million. All transactions carry the 10b5-1 flag, meaning they were pre-arranged. No open-market buying from any director or officer appears in the record. T. Rowe Price added over 2.2 million shares as of the September 30 disclosure, and Jennison Associates added a similar number, both meaningful accumulations at what were then materially higher prices. BlackRock trimmed slightly in its most recent filing.

The next scheduled earnings date is December 2, leaving 38 days for the current trajectory to either stabilise or steepen further. Given the stock's established pattern of large post-earnings moves and the short base sitting near a one-month high, how short positioning evolves into that date is the main thing to watch.